Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Annaly Capital Management, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while Annaly Capital Management, Inc. trades at $23.2 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 3.4× ACADIA Pharmaceuticals Inc.'s market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NLY | |
|---|---|---|
Market Cap | $5.07B | $17.44B |
Sector | Health | Financials |
52-Week High | $29.41 | $24.40 |
52-Week Low | $20.06 | $20.21 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.
Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
